Alexis Borisy
SlowingNamed in filings at Curie BioOn the current fund
- Board seats filed
- 9
Named in filings at Curie BioOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Prana Therapies | Biotech & pharma | November 2025 | None on file |
| Relay Therapeutics | Biotech & pharma | January 2024 | None on file |
| Tango Therapeutics | Biotech & pharma | August 2023 | Third Rock Ventures |
| Celsius Therapeutics | Biotech & pharma | May 2018 | Third Rock Ventures |
| Magenta Therapeutics | Biotech & pharma | November 2016 | Atlas Venture |
| Editas Medicine | Biotech & pharma | August 2015 | Atlas Venture, Bain Capital Life Sciences, Biomatics Capital Partners |
| Revolution Medicines | Biotech & pharma | December 2014 | Third Rock Ventures |
| Blueprint Medicines | Biotech & pharma | January 2014 | Third Rock Ventures |
| Forma Therapeutics Holdings | Biotech & pharma | December 2011 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Alexis Borisy on the board, based on 9 filed seats with a verified or cited source.